BR112018069111A2 - terapia de combinação para o tratamento de leucemia mieloide aguda - Google Patents

terapia de combinação para o tratamento de leucemia mieloide aguda

Info

Publication number
BR112018069111A2
BR112018069111A2 BR112018069111-9A BR112018069111A BR112018069111A2 BR 112018069111 A2 BR112018069111 A2 BR 112018069111A2 BR 112018069111 A BR112018069111 A BR 112018069111A BR 112018069111 A2 BR112018069111 A2 BR 112018069111A2
Authority
BR
Brazil
Prior art keywords
treatment
myeloid leukemia
acute myeloid
combination therapy
amino
Prior art date
Application number
BR112018069111-9A
Other languages
English (en)
Inventor
Bahceci Erkut
YAMAKI Yoko
Original Assignee
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc. filed Critical Astellas Pharma Inc.
Publication of BR112018069111A2 publication Critical patent/BR112018069111A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

a presente invenção refere-se a métodos, usos, e composições para o tratamento de leucemia mieloide aguda que inclui combinações terapeuticamente eficazes de 6-etil-3-({3-metóxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]fenil}amino)-5-(tetra-hidro-2h-piran-4-ilamino)pirazina-2-carboxamida, ou um seu sal, e 4-amino-1-ß-d-ribofuranosil-1,3,5-triazin-2(1h)-ona, ou um seu sal.
BR112018069111-9A 2016-03-29 2017-03-27 terapia de combinação para o tratamento de leucemia mieloide aguda BR112018069111A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662314700P 2016-03-29 2016-03-29
US62/314,700 2016-03-29
US201662368343P 2016-07-29 2016-07-29
US62/368,343 2016-07-29
PCT/JP2017/012293 WO2017170348A1 (en) 2016-03-29 2017-03-27 Combination therapy for the treatment of acute myeloid leukemia

Publications (1)

Publication Number Publication Date
BR112018069111A2 true BR112018069111A2 (pt) 2019-03-19

Family

ID=59965623

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018069111-9A BR112018069111A2 (pt) 2016-03-29 2017-03-27 terapia de combinação para o tratamento de leucemia mieloide aguda

Country Status (10)

Country Link
US (2) US20190117649A1 (pt)
EP (1) EP3436014A4 (pt)
JP (1) JP2019512495A (pt)
KR (1) KR20180124055A (pt)
CN (1) CN108883109A (pt)
BR (1) BR112018069111A2 (pt)
CA (1) CA3018155A1 (pt)
MX (1) MX2018011975A (pt)
RU (1) RU2018134167A (pt)
WO (1) WO2017170348A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021016522A2 (pt) 2019-02-22 2021-10-26 Hanmi Pharm. Co., Ltd. Composição farmacêutica para o tratamento da leucemia mieloide aguda
CN113490497A (zh) * 2019-02-22 2021-10-08 韩美药品株式会社 包括flt3抑制剂和低甲基化剂的用于治疗急性髓系白血病的药物组合物
KR20200102948A (ko) 2019-02-22 2020-09-01 한미약품 주식회사 Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물
CN113677330B (zh) * 2019-04-03 2023-10-31 安斯泰来制药株式会社 药物组合物
KR20210002015A (ko) 2019-06-27 2021-01-06 한미약품 주식회사 Flt3 저해제 및 화학치료제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물
WO2021074769A1 (en) * 2019-10-14 2021-04-22 Astrazeneca Ab Combination therapy for treating a hematological malignancy
CA3155215A1 (en) * 2019-10-21 2021-04-29 Srikant Viswanadha Compositions comprising a dhodh inhibitor for the treatment of acute myeloid leukemia
TW202340177A (zh) 2021-12-30 2023-10-16 美商拜歐米富士恩股份有限公司 作為 flt3抑制劑之吡嗪化合物

Also Published As

Publication number Publication date
RU2018134167A (ru) 2020-04-29
EP3436014A1 (en) 2019-02-06
JP2019512495A (ja) 2019-05-16
MX2018011975A (es) 2019-01-15
EP3436014A4 (en) 2019-11-27
CA3018155A1 (en) 2017-10-05
US20200360372A1 (en) 2020-11-19
KR20180124055A (ko) 2018-11-20
US20190117649A1 (en) 2019-04-25
WO2017170348A1 (en) 2017-10-05
RU2018134167A3 (pt) 2020-06-30
CN108883109A (zh) 2018-11-23

Similar Documents

Publication Publication Date Title
BR112018069111A2 (pt) terapia de combinação para o tratamento de leucemia mieloide aguda
BR112018007526A2 (pt) compostos de benzolactama como inibidores de proteína quinase
PH12020551315A1 (en) Benzoxazepin oxazolidinone compounds and methods of use
PH12018502710A1 (en) Heterocyclic compounds as immunomodulators
EA201891203A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
PH12019501941A1 (en) Jak inhibitors containing a 4-membered heterocyclic amide
EA201891494A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
CL2015002529A1 (es) Compuestos de tetrahidropirrolotiazina
CL2018002516A1 (es) Inhibidores de mcl-1 indólicos sustituidos.
MX2019009255A (es) Proteínas quiméricas dirigidas y sus usos.
MX2018016419A (es) Derivados de n-(sustituida-fenil)-sulfonamida como inhibidores de quinasa n-(sustituida-fenil)-sulfonamida.
EA201691872A1 (ru) Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
EA201992322A3 (ru) Соединения и композиции для лечения гематологических расстройств
MX2015013481A (es) Compuestos heterociclicos fusionados como inhibidores de proteina quinasa.
BR112017010882B8 (pt) Compostos de n-((het)-arilmetil)-heteroaril-carboxamidas como inibidores de calicreína plasmática e seus usos
PH12019502345A1 (en) Methods of treatment using a jak inhibitor compoud
PH12018502056A1 (en) Methods of treatment of cholestatic diseases
EA033284B1 (ru) ПРОИЗВОДНЫЕ 8-[6-[3-(АМИНО)ПРОПОКСИ]-3-ПИРИДИЛ]-1-ИЗОПРОПИЛ-ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА В КАЧЕСТВЕ СЕЛЕКТИВНЫХ МОДУЛЯТОРОВ КИНАЗЫ МУТАЦИИ АТАКСИИ-ТЕЛЕАНГИЭКТАЗИИ (ATM) ДЛЯ ЛЕЧЕНИЯ РАКА
PH12019500196A1 (en) Compounds and compositions and uses thereof
UY37466A (es) N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa
BR112019007763A2 (pt) composto de fórmula, composição farmacêutica, métodos para tratar uma doença ou condição, para tratar dores, para diminuir o fluxo de íons e para tratar prurido, uso de um composto e invenção
EA202090414A1 (ru) Соединения и их применение
UY37311A (es) Derivados de 5,7-dihidro-pirrolo-piridina
MX2016015738A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cancer.
PH12019500198A1 (en) Compounds and compositions and uses thereof

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2631 DE 08/06/2021 POR TER SIDO INDEVIDA.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements